Buy Or Sell Opportunity • Jun 26
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 49% to €0.058. The fair value is estimated to be €0.075, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Meanwhile, the company became loss making. お知らせ • Jun 18
SciDev Limited Confirms Earnings Guidance for the Fiscal Year 2026 SciDev Limited confirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue of AUD 82 million to AUD 87 million. New Risk • Jun 17
New major risk - Revenue and earnings growth Earnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 34% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€12.2m market cap, or US$14.0m). お知らせ • Feb 26
SciDev Limited Revises Earnings Guidance for the Year 2026 SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue. お知らせ • Feb 23
SciDev Limited to Report First Half, 2026 Results on Feb 26, 2026 SciDev Limited announced that they will report first half, 2026 results on Feb 26, 2026 お知らせ • Sep 17
SciDev Limited, Annual General Meeting, Nov 20, 2025 SciDev Limited, Annual General Meeting, Nov 20, 2025. お知らせ • Aug 25
SciDev Limited to Report Fiscal Year 2025 Results on Aug 27, 2025 SciDev Limited announced that they will report fiscal year 2025 results Pre-Market on Aug 27, 2025 お知らせ • Nov 21
SciDev Limited Announces Resignation of Simone Watt as Director As foreshadowed at today's 2024 Annual General Meeting, SciDev Ltd. announced the resignation of Simone Watt as Director of the Company. Simone joined the SciDev Board in October of 2018. She has provided six years of steadfast support and valued insights that have played a major role in the extraordinary growth and success of the business over that time. Her deep knowledge of relevant industries and markets has been invaluable to the Board and senior leadership team. お知らせ • Sep 27
SciDev Limited, Annual General Meeting, Nov 21, 2024 SciDev Limited, Annual General Meeting, Nov 21, 2024. Reported Earnings • Aug 28
Full year 2024 earnings released: EPS: AU$0.012 (vs AU$0.002 loss in FY 2023) Full year 2024 results: EPS: AU$0.012 (up from AU$0.002 loss in FY 2023). Revenue: AU$109.2m (up 22% from FY 2023). Net income: AU$2.18m (up AU$2.51m from FY 2023). Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 03
First half 2024 earnings released: EPS: AU$0 (vs AU$0 in 1H 2023) First half 2024 results: EPS: AU$0 (in line with 1H 2023). Revenue: AU$50.3m (up 1.5% from 1H 2023). Net income: AU$57.0k (up 111% from 1H 2023). Profit margin: 0.1% (in line with 1H 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. お知らせ • Sep 30
SciDev Limited, Annual General Meeting, Nov 21, 2023 SciDev Limited, Annual General Meeting, Nov 21, 2023. Agenda: To consider re-election of Directors. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022) Full year 2023 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2022). Revenue: AU$89.9m (up 62% from FY 2022). Net loss: AU$339.0k (loss narrowed 45% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. New Risk • Aug 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (€31.5m market cap, or US$34.0m). Reported Earnings • Feb 23
First half 2023 earnings released: EPS: AU$0 (vs AU$0.014 loss in 1H 2022) First half 2023 results: EPS: AU$0 (improved from AU$0.014 loss in 1H 2022). Revenue: AU$49.6m (up 105% from 1H 2022). Net income: AU$27.0k (up AU$2.33m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Nov 29
Independent & Non-Executive Director recently bought €52k worth of stock On the 25th of November, Dan O’Toole bought around 266k shares on-market at roughly €0.19 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €82k more in shares than they have sold in the last 12 months. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.023 profit in FY 2021) Full year 2022 results: AU$0.003 loss per share (down from AU$0.023 profit in FY 2021). Revenue: AU$56.2m (up 32% from FY 2021). Net loss: AU$616.0k (down 118% from profit in FY 2021). Over the next year, revenue is forecast to grow 21%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Feb 24
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: AU$0.014 loss per share (down from AU$0.003 profit in 1H 2021). Revenue: AU$24.1m (up 32% from 1H 2021). Net loss: AU$2.30m (down AU$2.73m from profit in 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 35%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Dec 06
Interim Chief Financial Officer Geoff Stephenson has left the company On the 6th of December, Geoff Stephenson's tenure as Interim Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Geoff's name. A total of 2 executives have left over the last 12 months. Reported Earnings • Sep 03
Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.007 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$44.2m (up 145% from FY 2020). Net income: AU$3.45m (up AU$4.33m from FY 2020). Profit margin: 7.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 168% per year, which means it is well ahead of earnings. Board Change • Sep 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Simone Watt is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Executive Departure • Jul 13
Non-Executive Chairman Trevor Jones has left the company On the 30th of June, Trevor Jones' tenure as Non-Executive Chairman ended after 13.5 years in the role. As of March 2021, Trevor still personally held 1.20m shares (€248k worth at the time). Trevor is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.25 years. Is New 90 Day High Low • Feb 18
New 90-day low: €0.42 The company is down 18% from its price of €0.51 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.39 per share. Reported Earnings • Feb 11
First half 2021 earnings released: EPS AU$0.003 (vs AU$0.002 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.3m (up 200% from 1H 2020). Net income: AU$427.5k (up AU$618.7k from 1H 2020). Profit margin: 2.3% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 10
Revenue beats expectations Revenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 58%, compared to a 5.1% growth forecast for the Chemicals industry in Germany. Is New 90 Day High Low • Nov 14
New 90-day high: €0.53 The company is up 32% from its price of €0.40 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period.